39.78
-0.96(-2.36%)
Currency In HKD
Sector
Healthcare
Industry
Biotechnology
Employees
665
First IPO Date
October 09, 2020
| Name | Title | Pay | Year Born |
| Yongqing Luo | CEO & Executive Director | 33.16M | 1970 |
| Ian Ying Woo | Chief Financial Officer, President & Executive Director | 16.59M | 1972 |
| Jason Brown | Chief Business Officer | 0 | 1973 |
| Wei Yang | Chief Scientific Officer | 0 | 1970 |
| Chonggang Xu Steve | Chief Legal & Compliance Officer | 0 | 1969 |
| Xu Liang Rico | Chief Product Officer | 0 | 1969 |
| Yifang Wu | Executive Chairman of the Board | 0 | 1969 |
| Leah Liu | Joint Company Secretary & Vice President of Investor Relations | 0 | N/A |
| Sandra Zeng | Chief Medical Officer | 0 | 1967 |
| Yee Wa Lau | Joint Company Secretary | 0 | 1973 |
Everest Medicines Limited, a biopharmaceutical company, engages in discovery, licensing, clinical development, and commercialization of therapies to address critical unmet medical needs in Greater China and other Asia Pacific markets. Its pipeline products include eleven clinical-stage drug candidates for the treatment of oncology, immunology, cardio-renal, and infectious diseases. Everest Medicines Limited was incorporated in 2017 and is headquartered in Shanghai, China.